[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital del Rio Hortega\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":185},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,76,109,132,157],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100643037","endoscopic-calcium-electroporation-in-gastric-tumors-100643037",false,"NCT07647731","Endoscopic Calcium Electroporation in Gastric Tumors","Evaluation of Endoscopic Calcium Electroporation in Gastric Tumors: A Minimally Invasive Treatment Strategy","GASTRIC-CaEP","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\n* Age ≥18 years.\n* Histologically confirmed gastric malignancy.\n* Presence of anemia and\u002For gastrointestinal bleeding secondary to gastric cancer.\n* Ability and willingness to provide written informed consent.\n\nIn addition, participants must meet at least one of the following conditions:\n\n* Patients considered unsuitable for surgical and\u002For oncological treatment with curative or palliative intent due to advanced age, frailty, or significant comorbidities (Charlson Comorbidity Index ≥3 and\u002For ECOG Performance Status ≥2), following multidisciplinary team assessment.\n* Patients with metastatic disease receiving palliative systemic therapy in whom CaEP is indicated for symptomatic control of tumor-related gastrointestinal bleeding.\n* Patients receiving neoadjuvant therapy who develop tumor-related gastrointestinal bleeding requiring bleeding control to avoid interruption of systemic treatment prior to surgery.\n* Patients who decline surgical and\u002For oncological treatment when CaEP is considered appropriate for symptomatic control of gastrointestinal bleeding.\n\nExclusion Criteria:\n\nParticipants meeting any of the following criteria will be excluded:\n\n* Pregnancy or breastfeeding.\n* Presence of an endoluminal prosthesis within the intended treatment area.\n* Implanted electrical devices (e.g., pacemakers, implantable cardioverter-defibrillators) when temporary deactivation is not feasible or procedural safety cannot be guaranteed.\n* Uncorrectable coagulation disorders.\n* Medical contraindication to deep sedation or therapeutic upper gastrointestinal endoscopy.\n* Estimated life expectancy of less than 1 month.\n* Refusal or inability to provide informed consent","ALL","18 Years",{"count":20,"type":21},28,"ESTIMATED","INTERVENTIONAL",[24],"NA","Brief Summary Background\n\nGastric cancer (GC) remains a major global public health challenge, ranking as the fifth most common malignancy worldwide and the third leading cause of cancer-related mortality. In 2018, approximately 1 million new cases and 783,000 deaths were reported globally. The median age at diagnosis is around 60 years, with relatively few cases occurring in younger patients.\n\nDespite advances in systemic therapies, up to 60% of patients are diagnosed with advanced-stage disease, and approximately 20% present with significant comorbidities that limit available treatment options. This highlights the need for effective, safe, and well-tolerated therapeutic alternatives, particularly for frail patients and those with advanced disease.\n\nIn this context, calcium electroporation (CaEP) has emerged as a novel therapeutic approach with the potential to address an important unmet clinical need. CaEP is a local, minimally invasive treatment that may provide effective control of debilitating symptoms such as tumor-related gastrointestinal bleeding, while improving patients' functional status and quality of life. Importantly, these benefits may be achieved without the additional morbidity and mortality associated with more invasive therapeutic interventions. The implementation of CaEP could represent a significant advance in the management of gastric cancer, particularly in patients with limited treatment options.\n\nPrimary Objective\n\nTo evaluate the efficacy and safety of calcium electroporation (CaEP) in controlling gastrointestinal bleeding secondary to gastric cancer in patients undergoing palliative treatment, either in combination with systemic therapy or in clinical situations where control of tumor-related bleeding is required.\n\nStudy Design\n\nThis is a multicenter, non-randomized, non-pharmacological interventional study with longitudinal follow-up.\n\nThe intervention consists of two scheduled sessions of endoscopic calcium electroporation (CaEP). The second procedure will be performed 4 weeks after the first treatment unless contraindicated for clinical reasons.\n\nPrimary Outcome Measure\n\nClinical control of gastrointestinal bleeding secondary to gastric neoplasia.\n\nStudy Population\n\nPatients with histologically confirmed gastric cancer who present with gastrointestinal bleeding symptoms or secondary anemia will be prospectively enrolled.\n\nEligible participants will include patients who are candidates for palliative treatment, either as monotherapy or in combination with systemic medical treatment and\u002For radiotherapy. Patients experiencing tumor-related bleeding during neoadjuvant treatment prior to surgery may also be included.\n\nEstimated Enrollment\n\nA total sample size of 25 evaluable patients is required. Assuming a 10% loss to follow-up, the planned enrollment is 28 patients.",[27],"Calcium Electroporation for Hemostasis in Gastric Neoplasms",[29,30,31,32],"BLEEDING","CALCIUM ELECTROPORATION","gastric neoplasms","hemostasis","NOT_YET_RECRUITING","2026-06-09",{"date":36,"type":37},"2026-06-15","ACTUAL",{"date":39,"type":21},"2026-06",{"date":41,"type":21},"2031-12",{"name":43,"class":44},"Hospital del Rio Hortega","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100540221","a-mobile-application-to-improve-the-quality-of-colonoscopy-in-colorectal-cancer-screening-program-prepcolon-app-100540221","NCT06314022","A Mobile Application to Improve the Quality of Colonoscopy in Colorectal Cancer Screening Program (PrepColon APP)","Design of a Mobile Application to Improve the Quality of Colonoscopy and Its Implementation in Colorectal Cancer Screening Program: a Randomized Multicenter Study (PrepColon APP Study)","PREPCOLON","Inclusion Criteria:\n\n* -Subjects between 50-69 years old from the CRC screening program with FIT (\\>100ng\u002Fml).\n* Informed consent granted in writing\n\nExclusion Criteria:\n\n* Refusal to give informed consent.\n* Those who do not have a smartphone with a minimum version of the operating system (Android 4.4 or iOS 14, which cover more than 99% of the terminals in use)\n* Symptomatic patients\n* Subjects at elevated risk of CRC due to family history or inherited polyposis diseases or inflammatory bowel disease","50 Years","74 Years",{"count":56,"type":21},470,[24],"Colonoscopy is the gold standard for the diagnosis and resection of preneoplastic lesions, allowing the prevention of colon cancer. A colonoscopy is more efficient with proper preparation of the colon, as it allows for a higher rate of adenoma detection and cecal intubation. In routine practice, up to 30% of colonoscopies are poorly prepared and 11% of patients do not show up for their appointment. Adenomas not visualized in the initial colonoscopy due to poor preparation reached 68% and the rate of undetected cancers was 66.7%. A proper colon cleanse is conditioned by different factors; among them, failure to comply with the diet and take laxatives poses 5 times the risk of having a deficient colon preparation. The purpose of our study is the design and implementation of an app that facilitates the preparation of colonoscopy and evaluates its impact on compliance with diet and laxative intake.",[60,61],"Colorectal Cancer","Premalignant Colon Lesions",[63,64,65],"quality colonoscopy","colorrectal cancer screening","mobile application","RECRUITING","2026-06-03",{"date":69,"type":37},"2026-06-04",{"date":71,"type":37},"2024-05-02",{"date":73,"type":21},"2027-01-30",{"name":43,"class":44},2,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100621875","phase-3-intraoperative-ultrasound-for-brain-tumor-surgery-enhanced-by-ai-100621875","NCT07376304","Intraoperative Ultrasound for Brain Tumor Surgery Enhanced by AI","Optimization of Intraoperative Ultrasound Use in Brain Tumor Surgery Through Artificial Intelligence-Based Techniques","BrainUS-AI","Inclusion criteria:\n\n* Age ≥ 18 years.\n* Scheduled for craniotomy and resection of a brain tumor with ioUS planned as part of the standard surgical workflow.\n* Preoperative MRI available for surgical planning.\n* Ability to obtain informed consent from the patient or legal representative.\n\nExclusion criteria:\n\n• Inadequate ioUS image acquisition due to technical failure or intraoperative complications unrelated to the tumor.",{"count":85,"type":21},100,[87],"PHASE3","Intraoperative ultrasound is a versatile, low-cost imaging tool that has been shown to improve safety and efficacy in brain tumor surgery. However, its widespread adoption remains limited due to operator dependency, the complexity of image interpretation, the presence of artifacts, and a restricted field of view.\n\nThis project aims to prospectively evaluate, in a multicenter and non-randomized setting, a prototype real-time deep learning-based segmentation model for brain tumor delineation in intraoperative ultrasound. The model is designed to facilitate the identification of tumor tissue during surgery, potentially enhancing intraoperative decision-making and surgical precision.\n\nBy increasing the precision and accessibility of ioUS, this innovation is expected to enable safer and more complete resections, with the potential to improve both survival and quality of life for patients with brain tumors.",[90],"Brain Tumor Adult",[92,93,94,95,96,97,98,99,100],"brain tumor","glioma","glioblastoma","low-grade glioma","high-grade glioma","ious","computer vision","AI","ultrasound","2026-01-22",{"date":103,"type":37},"2026-01-29",{"date":105,"type":21},"2026-03",{"date":107,"type":21},"2028-06",{"name":43,"class":44},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},"100458210","eus-guided-entero-biliary-anastomosis-for-therapeutic-access-in-benign-biliary-obstructions-100458210","NCT05246657","EUS-guided Entero-biliary Anastomosis for Therapeutic Access in Benign Biliary Obstructions","EUS-guided Entero-biliary Anastomosis as Fistulas for Therapeutic Access in Benign Biliary Obstructions Not Accessible by ERCP","ATENHEA","Inclusion Criteria:\n\n* • Consecutive patients ≥ 18 years old.\n\n  * Benign biliary obstruction.\n  * ERCP failed or where ERCP could not be performed due to surgically-altered anatomy\n\nExclusion Criteria:\n\n* • Refusal to sign the informed consent.\n\n  * Malignant biliary obstruction\n  * Coagulopathy (INR\\>1.5) or trombocytopenia (\\\u003C50,000 platelets\u002Fmm3) uncorrectable.\n  * Inability to tolerate the sedation necessary for the examination.\n  * Pregnancy or lactation.\n  * Unable to follow-up",{"count":118,"type":21},50,"OBSERVATIONAL","Background: Transpapillary EUS-BD (rendezvous\u002Fantegrade) is gaining acceptance in BBO. The potential of transmural EUS-BD (hepaticogastrostomy\u002Fcholedochoduodenostomy) in complex BBO warrants study.\n\nAims: To assess feasibility and efficacy of TEA using transmural covered self-expandable metal-stents (cSEMS) to provide interval biliary drainage and create TAF for biliary endotherapy under cholangioscopy or fluoroscopy in BBO not amenable to ERCP.",[122],"Cholangiopancreatography, Endoscopic Retrograde","2025-03-10",{"date":125,"type":37},"2025-03-11",{"date":127,"type":37},"2021-06-01",{"date":129,"type":21},"2026-07-01",{"name":43,"class":44},1,{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":140,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":148,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":151,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":131},"100356476","clinical-trial-comparing-ercp-vs-ercp-and-transmural-gall-bladder-drainage-100356476","NCT03921502","Clinical Trial Comparing ERCP vs ERCP and Transmural Gall Bladder Drainage","Randomized Multicentre Double-blind Clinical Trial Comparing ERCP vs ERCP and Transmural Gall Bladder Drainage in Non-surgical Patients With Symptomatic Choledocholithiasis","PECAS","Inclusion Criteria:\n\n* Symptomatic choledocholithiasis (choledocholithiasis demonstrated radiologically or highly suspected by clinical data (acute cholangitis or obstructive jaundice), analytical and imaging according to the criteria of high probability of choledocholithiasis established in the clinical guidelines (ASGE Guide).\n* Discarded for surgical treatment due to age, comorbidity or refusal of the patient.\n* Age\\>75 years\n\nExclusion Criteria:\n\n* Charlson comorbidity scale adjusted to age \\\u003C4.\n* Hepatobiliary surgery or previous superior digestive tract.\n* Ascitis.\n* Inability to tolerate sedation of endoscopy, perforation of the digestive tract or other contraindication to endoscopy.\n* Coagulopathy with INR (international normalized ratio) \\> 1.5 not correctable or thrombocytopenia \\\u003C50000 \u002F mm3 not correctable.\n* Other diagnoses at admission (acute cholecystitis, acute pancreatitis, biliopancreatic neoplasia).\n* Hemodynamic instability.\n* Urgent procedure performed after hours\n* No availability of expert material \u002F endoscopist in drainage.\n* Anatomical impossibility of performing biliary drainage (absence of vesicular distension, contact between gallbladder and stomach or duodenum, contact area \\\u003C10 mm).\n* Baseline ECOG (Easthern Cooperative Oncology Group) \\> = 4\n* Expectancy of survival \\\u003C6 months.\n* Refusal to participate.\n* Distance between the gallbladder and upper digestive tract\\> 1cm, scleroatrophic vesicle, lack of stable acoustic window for drainage\n* ERCP failed (inhability to dain common bile duct)","75 Years",{"count":142,"type":21},150,[24],"Cholelithiasis occurs in 10-20% of the general population. Up to 18% of these subjects will present symptoms. In patients with symptomatic choledocholithiasis who are not candidates for surgery with indication for ERCP, transmural drainage of the gallbladder reduces the risk of recurrence.\n\nThe investigators propose a multicentric double-blind randomized trial. Our primary objective is to assess whether ERCP associated with transmural gallbladder drainage is able to reduce biliary disease income compared with ERCP in patients not candidates for surgery with symptomatic choledocholithiasis and cholelithiasis during one year of follow-up. Also the investigators will analyze the proportion of technical success and complications.\n\nThe study population includes all patients older than 75 years with symptomatic choledocholithiasis. An estimated 75 subjects per group (ERCP alone and ERCP and transmural drainage) are needed.",[146,147],"Bile Duct; Obstruction, With Calculus","Choledocholithiasis",[147,149,150],"Gall Bladder drainage","LAMS",{"date":125,"type":37},{"date":153,"type":37},"2019-08-01",{"date":155,"type":21},"2026-05-01",{"name":43,"class":44},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":165,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":4},"100566580","artificial-intelligence-guided-radiotherapy-planning-for-glioblastoma-100566580","NCT06657027","Artificial Intelligence-Guided Radiotherapy Planning for Glioblastoma","Evaluation of the Efficacy and Safety of Personalized Radiotherapy Guided by Predictive Models of Tumor Infiltration, Combining Artificial Intelligence and Multiparametric MRI in Glioblastomas","ARTPLAN-GLIO","Inclusion Criteria:\n\n* Patients with a recent diagnosis of IDH wild-type glioblastoma, grade 4 according to the Central Nervous System Tumors classification of the World Health Organization of 2021.\n* Ability to undergo MRI studies.\n* Performance status with Karnofsky Performance Status (KPS) ≥ 60.\n* Life expectancy ≥ 12 weeks.\n* Laboratory results within the following ranges, obtained in the 14 days prior to enrollment:\n\n  * Leucocitos ≥ 3,000\u002FµL.\n  * Absolute neutrophils ≥ 1,500\u002FµL.\n  * Plaquetas ≥ 75,000\u002FµL.\n  * Hemoglobin ≥ 9.0 g\u002FdL (transfusion is allowed to reach the minimum level).\n  * Glutamic-oxaloacetic transaminase (SGOT) ≤ 2 times the upper limit of normal.\n  * Bilirubin ≤ 2 times the upper limit of normal.\n  * Creatinina ≤ 1.5 mg\u002FdL.\n* Women of childbearing age must present a negative pregnancy test ≤ 14 days prior to enrollment.\n* Ability to understand and sign the informed consent.\n* Willingness to refrain from other cytotoxic or noncytotoxic therapies against the tumor during the protocol.\n\nExclusion Criteria:\n\n* Presence of pacemakers, neurostimulators, cochlear implants, metal in ocular structures, or work history that compromise safety in MRI.\n* Significant medical illnesses that may compromise tolerance to treatment, at the discretion of the investigator.\n* History of invasive cancer in the last 3 years, with few exceptions.\n* Active infections or serious intercurrent illnesses.\n* Previous treatments with cytotoxic, noncytotoxic, experimental agents, or cranial radiation therapy.\n* Maximum radiation target volume (GTV3) greater than 65 cc.","15 Years",{"count":167,"type":21},40,"The ARTPLAN-GLIO study aims to evaluate the feasibility and effectiveness of integrating artificial intelligence in personalized radiotherapy planning for glioblastomas. On the basis of previous work by our group, where a predictive model was developed from radiological characteristics extracted from MR images, this project will evaluate the use of tumor infiltration probability maps in radiotherapy planning.\n\nCurrently, radiotherapy treatment uses margins defined by population studies, without considering the individual characteristics of the patients. Although 80% of recurrences occur in peritumoral areas close to the surgical margins, treatment volumes are not customized owing to the lack of techniques that distinguish between edema and infiltrated tumor tissue.\n\nOur recurrence probability maps address this limitation and could improve radiation planning. In this study, the volumes and doses of radiotherapy were adjusted according to the predictions of the model, with a focus on high-risk areas to optimize local control and reduce toxicity in healthy tissues.\n\nSurvival results will be compared between patients treated with personalized AI-guided radiotherapy and a historical cohort with standard treatment. In addition, the safety of the approach will be evaluated by adverse event analysis. Finally, an accessible online platform with the potential to transform glioblastoma treatment and improve patient survival will be developed to implement this predictive model.",[170],"Glioblastoma",[172,173,174,94,175,176],"radiotherapy","oncology","artificial intelligence","personalized radiotherapy","precision medicine","2024-10-22",{"date":179,"type":37},"2024-10-24",{"date":181,"type":21},"2025-01-01",{"date":183,"type":21},"2027-06-30",{"name":43,"class":44},""]